Income Taxes (Tables)
|
12 Months Ended |
Mar. 31, 2024 |
Income Taxes [Abstract] |
|
Schedule of Reconciliations of the Differences between the Income Tax Expenses |
Reconciliations of the differences
between the income tax expenses of the Company and the PRC statutory EIT rate applicable to losses of the consolidated entities are as
follows:
| |
Year ended March 31, 2022 | | |
Year ended March 31, 2023 | | |
Year ended March 31, 2024 | |
| |
RMB | | |
RMB | | |
RMB | |
| |
| | | |
| | | |
| | |
Loss before income taxes | |
| (134,812 | ) | |
| (106,805 | ) | |
| (69,875 | ) |
Income tax computed at respective applicable tax rates | |
| (33,702 | ) | |
| (26,701 | ) | |
| (17,469 | ) |
Effect of different tax jurisdiction | |
| 2,341 | | |
| 12,323 | | |
| 6,976 | |
Super deduction for research and development expenses (a) | |
| (1,881 | ) | |
| (456 | ) | |
| (547 | ) |
Non-deductible expenses | |
| 97 | | |
| 728 | | |
| 115 | |
Change in valuation allowance | |
| 34,716 | | |
| 15,017 | | |
| 11,852 | |
Total | |
| 1,571 | | |
| 911 | | |
| 927 | |
(a) | According to the relevant laws and regulations promulgated
by the State Administration of Tax of the PRC, from 2013 onwards, enterprises engaging in research and development activities are entitled
to claim 200% of their qualified research and development expenses so incurred as tax deductible expenses. The additional deduction of
100% of qualified research and development expenses (the “Super Deduction”) can be directly claimed in the annual EIT filing.
For the years end March 31, 2022, 2023 and 2024, the Super Deduction for research and development expenses available to the Company amounted
to RMB1.9 million, RMB0.5 million and RMB0.5 million, respectively. |
|
Schedule of Effect of Tax Holiday |
The following table sets forth the
effect of tax holiday effect on China operations:
| |
Year ended March 31, 2022 | | |
Year ended March 31, 2023 | | |
Year ended March 31, 2024 | |
| |
RMB | | |
RMB | | |
RMB | |
| |
| | | |
| | | |
| | |
Tax holiday effect | |
| 3,513 | | |
| 1,235 | | |
| 1,882 | |
Basic and diluted net loss per share effect | |
| 0.05 | | |
| 0.02 | | |
| 0.02 | |
|
Schedule of Effective Income Tax Rate and the PRC Statutory Income Tax Rates |
Reconciliations between the effective income tax
rate and the PRC statutory income tax rates are as follows:
| |
Year ended March 31, 2022 | | |
Year ended March 31, 2023 | | |
Year ended March 31, 2024 | |
| |
RMB | | |
RMB | | |
RMB | |
| |
| | | |
| | | |
| | |
PRC statutory income tax rates | |
| 25 | % | |
| 25 | % | |
| 25 | % |
Tax holiday effect | |
| 3 | % | |
| (1 | )% | |
| (3 | )% |
Difference in tax rates of subsidiaries outside PRC | |
| (8 | )% | |
| (10 | )% | |
| (5 | )% |
Super deduction for research and development expenses | |
| 1 | % | |
| 0 | % | |
| 1 | % |
Non-deductible expenses | |
| 0 | % | |
| 1 | % | |
| 0 | % |
Change in valuation allowance | |
| (20 | )% | |
| (14 | )% | |
| (17 | )% |
Effective income tax rate | |
| 1 | % | |
| 1 | % | |
| 1 | % |
|
Schedule of Current and Deferred Portions of Income Tax Expenses |
The current and deferred portions of
income tax expenses included in the consolidated statements of operations and comprehensive loss are as follows:
| |
Year ended March 31, 2022 | | |
Year ended March 31, 2023 | | |
Year ended March 31, 2024 | |
| |
RMB | | |
RMB | | |
RMB | |
| |
| | | |
| | | |
| | |
Current income tax expense/(benefit) | |
| (582 | ) | |
| 78 | | |
| (20 | ) |
Deferred tax benefit | |
| (989 | ) | |
| (989 | ) | |
| (907 | ) |
Income tax credit, net | |
| (1,571 | ) | |
| (911 | ) | |
| (927 | ) |
|
Schedule of Deferred Tax Assets and Tax Liabilities |
The tax effects of temporary differences that give rise
to the deferred tax asset and liabilities balances as of March 31, 2023 and 2024 are as follows:
| |
As of March 31, | | |
As of March 31, | |
| |
2023 | | |
2024 | |
| |
RMB | | |
RMB | |
| |
| | |
| |
Deferred tax assets: | |
| | |
| |
Net accumulated loss-carry forward | |
| 163,526 | | |
| 150,667 | |
Allowance | |
| 238 | | |
| 861 | |
Contract liabilities | |
| 172 | | |
| 60 | |
Accruals | |
| 842 | | |
| 889 | |
Fair Value Change | |
| 1,891 | | |
| 2,778 | |
Less: Valuation allowance | |
| (166,669 | ) | |
| (155,255 | ) |
| |
| | | |
| | |
Deferred tax liabilities: | |
| | | |
| | |
Recognition of intangible assets arising from asset acquisition and business combination | |
| (4,141 | ) | |
| (3,234 | ) |
|
Schedule of Movement of Valuation Allowance |
Movement of valuation allowance is as follows:
| |
Year ended March 31, 2022 | | |
Year ended March 31, 2023 | | |
Year ended March 31, 2024 | |
| |
RMB | | |
RMB | | |
RMB | |
| |
| | |
| | |
| |
Beginning balance | |
| 149,978 | | |
| 177,247 | | |
| 166,669 | |
Change of valuation allowance | |
| 27,269 | | |
| 15,017 | | |
| 11,852 | |
Written-off for expiration of net operating losses | |
| - | | |
| (22,995 | ) | |
| (23,266 | ) |
Decrease of valuation allowances related to the disposal of a subsidiary | |
| - | | |
| (2,600 | ) | |
| - | |
Ending balance | |
| 177,247 | | |
| 166,669 | | |
| 155,255 | |
|